A recent study published in Volume 12 of Oncoscience on October 14, 2025, has confirmed that the OVCAR3 cell line is a reliable model for high-grade serous ovarian carcinoma (HGSOC), which is the most lethal form of ovarian cancer. The research was led by Faisal Iqbal from the University of Illinois Chicago.
The study used genetic sequencing and cell death analysis to compare the OVCAR3 cell line with clinical samples of HGSOC. Researchers employed Sanger sequencing, a commonly used and cost-effective method, to analyze the TP53 gene. They found that both laboratory and clinical samples had the same non-mutated version of this gene, which is frequently altered in ovarian cancer cases. This result supports using OVCAR3 as a representative model for studying HGSOC.
"The most prevalent and aggressive subtype of epithelial ovarian cancer is high grade serous ovarian carcinoma (HGSOC) – approximately 70% of all ovarian cancer cases," according to the study.
The research also examined how two repurposed drugs—metformin and chlorpromazine (CPZ)—affect ovarian cancer cells. Tests showed that while each drug had moderate effects when used alone, their combination led to a significant reduction in cancer cell survival. These findings were consistent across both laboratory models and clinical samples.
The authors highlight that genetically validated models like OVCAR3 are important for preclinical testing and developing targeted therapies for ovarian cancer. The continued use of Sanger sequencing remains valuable in ensuring these models accurately reflect human disease.
